Form 4: Sutro Biopharma Director Connie Matsui Granted 50,000 Stock Options

Sutro Biopharma, Inc. director Connie Matsui was granted 50,000 stock options with an exercise price of $0.85 per share, vesting monthly from July 6, 2025.

Summary

• Connie Matsui, a Director of Sutro Biopharma, Inc. (STRO), was granted 50,000 stock options.
• The transaction date for this grant was June 6, 2025.
• The exercise price for these stock options is $0.85 per share.
• The options will vest at a rate of 8.33% of the total shares monthly, commencing July 6, 2025.
• Full vesting (100%) will occur on the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026, contingent on Ms. Matsui's continued service to the issuer.
• The expiration date for these stock options is June 6, 2035.
• Following this transaction, Connie Matsui beneficially owns 50,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with the long-term performance of the company and shareholder value, reflecting standard compensation practices. It does not, however, indicate a significant operational or financial breakthrough.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company and shareholder value.
• The exercise price of $0.85 per share is relatively low, potentially offering significant upside if the company's stock price appreciates.

Future Outlook

This Form 4 filing does not provide a general future outlook for the company, but it details the vesting schedule for the granted stock options, indicating future exercisability contingent on continued service.

Industry Context

The grant of stock options to a director is a common practice in the biopharmaceutical industry, as well as across many other sectors, serving as a form of long-term incentive compensation to align the interests of board members with those of shareholders.

Comparison to Industry Standards

• The granting of stock options to non-employee directors is a standard component of compensation packages across publicly traded companies, including those in the biopharma sector.
• The vesting schedule, which includes monthly vesting and full vesting by the next annual meeting or a specific date, is typical for such equity grants, similar to practices observed at companies like Amgen Inc. or Gilead Sciences, Inc. for their board members.
• The exercise price being a fixed value at the time of grant is also standard for stock options, differentiating them from restricted stock units (RSUs) which typically have a zero exercise price.

Related Party Transactions

• The document details the grant of 50,000 stock options to Connie Matsui, a Director of Sutro Biopharma, Inc., which constitutes a transaction with a related party (an insider).

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's incentives with shareholder interests, potentially leading to decisions that enhance long-term shareholder value.
• Employees: While not directly impacting all employees, such compensation practices for leadership can influence overall company compensation philosophy and morale.

Next Steps

• The stock options will continue to vest monthly starting July 6, 2025, subject to Connie Matsui's continued service.
• The options will become fully vested and exercisable by the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026.
• Connie Matsui may choose to exercise the vested options at any time before their expiration date of June 6, 2035.

Key Dates

Recommendation

Keywords

Sutro Biopharma, STRO, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biopharma